'Obligate' anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice

Li,Chang‑Xian; Yu,Bin; Shi,Lei; Geng,Wei; Lin,Qiu‑Bin; Ling,Chang‑Chun; Yang,Mei; Ng,Kevin T. P.; Huang,Jian‑Dong; Man,Kwan

doi:10.3892/ol.2016.5453

'Obligate' anaerobic Salmonella strain YB1 suppresses liver tumor growth and metastasis in nude mice

Authors:
- Chang‑Xian Li
- Bin Yu
- Lei Shi
- Wei Geng
- Qiu‑Bin Lin
- Chang‑Chun Ling
- Mei Yang
- Kevin T. P. Ng
- Jian‑Dong Huang
- Kwan Man
View Affiliations

Affiliations: Department of Surgery and Centre for Cancer Research, University of Hong Kong, Hong Kong 999077, SAR, P.R. China, Department of Biochemistry and Shenzhen Institute of Research and Innovation, University of Hong Kong, Hong Kong 999077, SAR, P.R. China
Published online on: November 30, 2016 https://doi.org/10.3892/ol.2016.5453
Pages: 177-183
Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The antitumor properties of bacteria have been demonstrated over the past decades. However, the efficacy is limited and unclear. Furthermore, systemic infection remains a serious concern in bacteria treatment. In this study, the effect of YB1, a rationally designed ‘obligate’ anaerobic Salmonella typhimurium strain, on liver tumor growth and metastasis in a nude mouse orthotopic liver tumor model was investigated. The orthotopic liver tumor model was established in nude mice using the hepatocellular carcinoma cell line MHCC‑97L. Two weeks after orthotopic liver tumor implantation, YB1, SL7207 and saline were respectively administered through the tail vein of the mice. Longitudinal monitoring of tumor growth and metastasis was performed using Xenogen IVIS, and direct measurements of tumor volume were taken 3 weeks after treatment. In vitro, MHCC‑97L and PLC cells were incubated with YB1 or SL7207 under anaerobic conditions. YB1 was observed to invade tumor cells and induce tumor cell apoptosis and death. The results revealed that all mice in the YB1 group were alive 3 weeks after YB1 injection while all mice in the SL7207 group died within 11 days of the SL7207 injection. The body weight decreased by ~9% on day 1 after YB1 injection and but subsequently recovered. Liver tumor growth and metastases were significantly inhibited following YB1 treatment. By contrast to the control group, a large number of Gr1‑positive cells were detected on days 1 to 21 following YB1 treatment. Furthermore, YB1 also effectively invaded tumor cells and induced tumor cell apoptosis and death. In conclusion, YB1 suppressed liver tumor growth and metastasis in a nude mice liver tumor model. The potential mechanism may be through enhancing innate immune response and inducing tumor cell apoptosis and cell death.

View Figures

View References

1	Bosch FX, Ribes J, Díaz M and Cléries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology. 127:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
2	Doi K, Horiuchi T, Uchinami M, Tabo T, Kimura N, Yokomachi J, Yoshida M and Tanaka K: Hepatic ischemia-reperfusion promotes liver metastasis of colon cancer. J Surg Res. 105:243–247. 2002. View Article : Google Scholar : PubMed/NCBI
3	van der Bilt JD, Kranenburg O, Nijkamp MW, Smakman N, Veenendaal LM, Te Velde EA, Voest EE, van Diest PJ and Rinkes IH Borel: Ischemia/reperfusion accelerates the outgrowth of hepatic micrometastases in a highly standardized murine model. Hepatology. 42:165–175. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bruix J, Llovet JM, Castells A, Montañá X, Brú C, Ayuso MC, Vilana R and Rodés J: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology. 27:1578–1583. 1998. View Article : Google Scholar : PubMed/NCBI
5	Ahn J and Flamm SL: Hepatocellular carcinoma. Dis Mon. 50:556–573. 2004. View Article : Google Scholar : PubMed/NCBI
6	Wall DM, Srikanth CV and McCormick BA: Targeting tumors with salmonella Typhimurium - potential for therapy. Oncotarget. 1:721–728. 2010. View Article : Google Scholar : PubMed/NCBI
7	Pawelek JM, Low KB and Bermudes D: Tumor-targeted Salmonella as a novel anticancer vector. Cancer Res. 57:4537–4544. 1997.PubMed/NCBI
8	Nauts HC, Fowler GA and Bogatko FH: A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man; a critical analysis of 30 inoperable cases treated by Coley's mixed toxins, in which diagnosis was confirmed by microscopic examination selected for special study. Acta Med Scand Suppl. 276:1–103. 1953.PubMed/NCBI
9	Barbé S, Van Mellaert L and Anné J: The use of clostridial spores for cancer treatment. J Appl Microbiol. 101:571–578. 2006. View Article : Google Scholar : PubMed/NCBI
10	Van Mellaert L, Barbé S and Anné J: Clostridium spores as anti-tumour agents. Trends Microbiol. 14:190–196. 2006. View Article : Google Scholar : PubMed/NCBI
11	Sasaki T, Fujimori M, Hamaji Y, Hama Y, Ito K, Amano J and Taniguchi S: Genetically engineered Bifidobacterium longum for tumor-targeting enzyme-prodrug therapy of autochthonous mammary tumors in rats. Cancer Sci. 97:649–657. 2006. View Article : Google Scholar : PubMed/NCBI
12	Li X, Fu GF, Fan YR, Liu WH, Liu XJ, Wang JJ and Xu GX: Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. Cancer Gene Ther. 10:105–111. 2003. View Article : Google Scholar : PubMed/NCBI
13	Patyar S, Joshi R, Byrav DS, Prakash A, Medhi B and Das BK: Bacteria in cancer therapy: a novel experimental strategy. J Biomed Sci. 17:212010. View Article : Google Scholar : PubMed/NCBI
14	Minton NP: Clostridia in cancer therapy. Nat Rev Microbiol. 1:237–242. 2003. View Article : Google Scholar : PubMed/NCBI
15	Bacon GA, Burrows TW and Yates M: The effects of biochemical mutation on the virulence of bacterium typhosum: the induction and isolation of mutants. Br J Exp Pathol. 31:702–713. 1950.
16	Forbes NS, Munn LL, Fukumura D and Jain RK: Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors. Cancer Res. 63:5188–5193. 2003.PubMed/NCBI
17	Loessner H, Endmann A, Leschner S, Westphal K, Rohde M, Miloud T, Hämmerling G, Neuhaus K and Weiss S: Remote control of tumour-targeted Salmonella enterica serovar Typhimurium by the use of L-arabinose as inducer of bacterial gene expression in vivo. Cell Microbiol. 9:1529–1537. 2007. View Article : Google Scholar : PubMed/NCBI
18	Royo JL, Becker PD, Camacho EM, Cebolla A, Link C, Santero E and Guzmán CA: In vivo gene regulation in Salmonella spp. by a salicylate-dependent control circuit. Nat Methods. 4:937–942. 2007. View Article : Google Scholar : PubMed/NCBI
19	Westphal K, Leschner S, Jablonska J, Loessner H and Weiss S: Containment of tumor-colonizing bacteria by host neutrophils. Cancer Res. 68:2952–2960. 2008. View Article : Google Scholar : PubMed/NCBI
20	Yu B, Yang M, Shi L, Yao Y, Jiang Q, Li X, Tang LH, Zheng BJ, Yuen KY, Smith DK, et al: Explicit hypoxia targeting with tumor suppression by creating an ‘obligate’ anaerobic Salmonella Typhimurium strain. Sci Rep. 2:4362012. View Article : Google Scholar : PubMed/NCBI
21	Hoiseth SK and Stocker BA: Aromatic-dependent Salmonella typhimurium are non-virulent and effective as live vaccines. Nature. 291:238–239. 1981. View Article : Google Scholar : PubMed/NCBI
22	Li CX, Shao Y, Ng KT, Liu XB, Ling CC, Ma YY, Geng W, Fan ST, Lo CM and Man K: FTY720 suppresses liver tumor metastasis by reducing the population of circulating endothelial progenitor cells. PLoS One. 7:e323802012. View Article : Google Scholar : PubMed/NCBI
23	Saccheri F, Pozzi C, Avogadri F, Barozzi S, Faretta M, Fusi P and Rescigno M: Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. Sci Transl Med. 2:44ra57. 2010. View Article : Google Scholar : PubMed/NCBI
24	Nishikawa H, Sato E, Briones G, Chen LM, Matsuo M, Nagata Y, Ritter G, Jäger E, Nomura H, Kondo S, et al: In vivo antigen delivery by a Salmonella typhimurium type III secretion system for therapeutic cancer vaccines. J Clin Invest. 116:1946–1954. 2006. View Article : Google Scholar : PubMed/NCBI
25	al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Bashir G and Chouaib S: Potent anti-tumor activity of systemically-administered IL2-expressing Salmonella correlates with decreased angiogenesis and enhanced tumor apoptosis. Clin Immunol. 130:89–97. 2009. View Article : Google Scholar : PubMed/NCBI
26	Avogadri F, Martinoli C, Petrovska L, Chiodoni C, Transidico P, Bronte V, Longhi R, Colombo MP, Dougan G and Rescigno M: Cancer immunotherapy based on killing of Salmonella-infected tumor cells. Cancer Res. 65:3920–3927. 2005. View Article : Google Scholar : PubMed/NCBI
27	Al-Ramadi BK, Fernandez-Cabezudo MJ, El-Hasasna H, Al-Salam S, Attoub S, Xu D and Chouaib S: Attenuated bacteria as effectors in cancer immunotherapy. Ann N Y Acad Sci. 1138:351–357. 2008. View Article : Google Scholar : PubMed/NCBI
28	Wall DM, Nadeau WJ, Pazos MA, Shi HN, Galyov EE and McCormick BA: Identification of the Salmonella enterica serotype typhimurium SipA domain responsible for inducing neutrophil recruitment across the intestinal epithelium. Cell Microbiol. 9:2299–2313. 2007. View Article : Google Scholar : PubMed/NCBI
29	Srikanth CV, Wall DM, Maldonado-Contreras A, Shi HN, Zhou D, Demma Z, Mumy KL and McCormick BA: Salmonella pathogenesis and processing of secreted effectors by caspase-3. Science. 330:390–393. 2010. View Article : Google Scholar : PubMed/NCBI
30	Ghavami S, Hashemi M, Ande SR, Yeganeh B, Xiao W, Eshraghi M, Bus CJ, Kadkhoda K, Wiechec E, Halayko AJ and Los M: Apoptosis and cancer: mutations within caspase genes. J Med Genet. 46:497–510. 2009. View Article : Google Scholar : PubMed/NCBI